Hayder Myriam, Varilh Marjorie, Turrin Cédric-Olivier, Saoudi Abdelhadi, Caminade Anne-Marie, Poupot Rémy, Liblau Roland S
Laboratoire de Chimie de Coordination CNRS UPR8241-205 , route de Narbonne, 31077-BP44099 Toulouse Cedex 4 France.
UPS-INPT, Université de Toulouse , F31077 Toulouse Cedex 4, France.
Biomacromolecules. 2015 Nov 9;16(11):3425-33. doi: 10.1021/acs.biomac.5b00643. Epub 2015 Oct 7.
Dendrimers are polyfunctional nano-objects of perfectly defined structure that can provide innovative alternatives for the treatment of chronic inflammatory diseases, including multiple sclerosis (MS). To investigate the efficiency of a recently described amino-bis(methylene phosphonate)-capped ABP dendrimer as a potential drug candidate for MS, we used the classical mouse model of MOG35-55-induced experimental autoimmune encephalomyelitis (EAE). Our study provides evidence that the ABP dendrimer prevents the development of EAE and inhibits the progression of established disease with a comparable therapeutic benefit as the approved treatment Fingolimod. We also show that the ABP dendrimer redirects the pathogenic myelin-specific CD4(+) T cell response toward IL-10 production.
树枝状大分子是结构完全明确的多官能纳米物体，可为包括多发性硬化症（MS）在内的慢性炎症性疾病的治疗提供创新的替代方案。为了研究最近描述的氨基双（亚甲基膦酸酯）封端的ABP树枝状大分子作为MS潜在候选药物的有效性，我们使用了MOG35 - 55诱导的实验性自身免疫性脑脊髓炎（EAE）经典小鼠模型。我们的研究提供了证据，表明ABP树枝状大分子可预防EAE的发展，并抑制已发病症的进展，其治疗效果与已批准的治疗药物芬戈莫德相当。我们还表明，ABP树枝状大分子可将致病性髓鞘特异性CD4(+) T细胞反应重定向为产生白细胞介素-10。
